Unfortunately, BMD losses with DMPA-SQ 104 mg at 3 years were found to be no different from those seen with IM DMPA, [15] although the potential for self-administration has not been totally dismissed.

Even though the product may not undergo significant changes, enthusiasm for it may be restored once clinicians become more aware of the reversibility of DMPA's impact on BMD. In addition ...